New York-based Bristol-Myers Squibb Co.'s CTLA-4 blocker Yervoy (ipilimumab) won FDA clearance in April 2011 , and another drug given the nod that summer was the kinase inhibitor for patients with the BRAF V600E mutation, Zelboraf (vemurafenib, Daiichi Sankyo Co. Ltd. and Roche AG). (See BioWorld Today, April 4, 2011, and Aug, 18, 2011.) It was those two approvals against which analysts weighed the chances of Thousand Oaks, Calif.-based Amgen Inc.'s talimogene laherparepvec, or T-VEC, brought

Inc. (Whitehouse Station, N.J.) Bristol-Myers Squibb Co. (New York) ND Nonexclusive deal to conduct a Phase II trial of a once-daily oral combination regimen consisting of BMS' NS5A replication complex inhibitor daclatasvir and Merck's NS3/4A protease inhibitor MK-5172 to treat chronic hepatitis C virus Merck will conduct the trial 4/23/13 Merck KGgA (Darmstadt, Germany) Pfizer Inc. (New York) ND Extended collaboration signed in 2002 by Merck's subsidiary EMD Serono Inc

Merck gains worldwide commercialization rights and will pay royalties to Abide 5/3/13 Adaptive Biotechnologies (Seattle) Bristol-Myers Squibb Co. (New York) ND Collaboration for the discovery of immunological biomarkers in oncology Adaptive will use its immune profiling assay, immunoSEQ, to identify potential biomarkers that may inform about drug response 5/10/13 Afraxis Inc. (San Diego) Institut de Recherches Servier (Paris) ND Nonexclusive collaboration to use the enhanced spine platform

Bristol-Myers Squibb Co., of New York, said it has notified the New York Stock Exchange (NYSE) of its intention to voluntarily delist its $2 convertible preferred stock from the NYSE, a decision driven by the low number of shares outstanding, low daily trading volume, listing fees and compliance administration costs

Nivolumab Wows as Companion to Yervoy Jedd Wolchok, medical oncologist at the Memorial Sloan-Kettering Cancer Center and the study lead on clinical trials that led to the approval of Yervoy (ipilimumab, Bristol-Myers Squibb Co.), provided the overview of a second ASCO abstract focusing on cancer immunotherapy, sponsored by BMS

Bristol-Myers Squibb Co. (New York) BMS-791325 Used in a combination regimen with dactlatasvir and asunaprevir Hepatitis C virus genotype 1 Interim Phase II data demonstrated sustained virologic response of up to 94% 4/24/13 Gilead Sciences Inc. (Foster City, Calif.) GS-7977 Sofosbuvir Hepatitis C virus genotypes 2 and 3, and genotypes 1, 4, 5 or 6 In three randomized trials, the rate of sustained virologic response after 12 weeks ranged from 50% for treatment-experienced patients to 78% for

signed another deal with Bristol-Myers Squibb Co

Adaptive Biotechnologies, of Seattle, entered a collaboration with Bristol-Myers Squibb Co., of New York, for the discovery of immunological biomarkers in oncology

Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, showing that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliqus (apixaban) compared to warfarin were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation

Bristol-Myers Squibb Co. (BMS), of New York, disclosed results from a 12-month subgroup analysis of a National Institutes of Health, open-label, long-term research study of metreleptin, an investigational agent for the treatment of metabolic disorders associated with inherited or acquired lipodystrophy (LD

Bristol-Myers Squibb Co., of New York, said the FDA approved a supplemental new drug application for the HIV-1 therapy Sustiva (efavirenz), including dosing recommendations for HIV-1 infected pediatric patients three months to three years old and weighing at least 3.5 kg

An existing partner with two other deals jumped aboard Ambrx Inc.'s site-specific, antibody drug conjugate (ADC) bandwagon, as Bristol-Myers Squibb Co

Any summary of 2012 deals would be incomplete without pointing up the unusual alliance between Bristol-Myers Squibb Co

Any summary of 2012 deals would be incomplete without pointing up the unusual alliance between Bristol-Myers Squibb Co

Of the orphan drugs in the pipeline, the report indicates that elotuzumab (AbbVie/Bristol-Myers Squibb Co.) indicated in multiple myeloma is the most valuable.

Mendlein's roles in biotech include both start-up firms such as aTyr and Fate Therapeutics Inc., and he's also had experience joining established firms such as Adnexus Inc. (then named Compound Therapeutics Inc.), which he led through the acquisition by Bristol-Myers Squibb Co. (See BioWorld Today, Sept. 25, 2007.) "I want to work wherever it makes sense," he said, adding that he looks for opportunities that are "productive, fun and exciting

Bristol-Myers Squibb Co., of New York, announced interim Phase II data demonstrating sustained virologic response of up to 94 percent, in treatment-naïve, genotype 1 chronic hepatitis C patients, at time points ranging from four to 36 weeks post-treatment depending on the treatment group, in patients treated with combination regimens of daclatasvir, asunaprevir and BMS-791325...The company said the data "support Vertex's recently announced non-exclusive agreement with Bristol-Myers Squibb Company

Among the orphan drugs in the pipeline, the report contended that elotuzumab (AbbVie, Bristol-Myers Squibb Co.) indicated in multiple myeloma is the most valuable.